Trial Designs
Trial Designs
1L, first-line; 2L, second-line; aBC, advanced breast cancer; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; CI, confidence interval; ET, endocrine therapy; FUL,...
1L, first-line; 2L, second-line; aBC, advanced breast cancer; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; CI, confidence interval; ET, endocrine therapy; FUL,...
References: 1. KISQALI Prescribing Information Nov 2019.SIN Novartis Singapore. 2. Tripathy D, Im S–A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women...